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Background: Taxol, a promising
agent for the treatment of cancer,
has entered phase II clinical trials.
Nevertheless, it belongs to the class
of compounds that show impaired re-
tention in multidrug-resistant cells
expressing P-glycoprotein (Pgp), a
drug efflux pump. Chemosensitizers
like verapamil modulate multidrug
resistance by interfering with the
efflux action of Pgp and thus can
decrease drug resistance or can re-
store drug sensitivity by restoring
normal drug accumulation and dis-
tribution within the multidrug-
resistant tumor cell. The two
strongest, nearly equipotent chemo-
sensitizers identified to date are the
cyclosporine derivative SDZ PSC 833
and the semisynthetic cyclopeptolide
SDZ 280-446. Purpose: This study
was designed to investigate the ca-
pacities of verapamil, SDZ PSC 833,
and SDZ 280-446 to decrease resist-
ance of two multidrug-resistant cell
lines to taxol. Methods: We studied in
vitro the growth of two multidrug-
resistant tumor cell lines displaying
high resistance to taxol: multidrug-
resistant Chinese hamster ovary cells
and murine monocytic leukemia P388
cells. We determined the taxol con-
centration that produced 50% inhibi-
tion of cell growth (IC^) in the two
multidrug-resistant cell lines and in
the parent cell lines, in the presence
of a range of chemosensitizer con-
centrations (0-30 \iM). ICJO values
were determined in the presence and
in the absence of verapamil, SDZ
PSC 833, or SDZ 280-446. Results:
At nontoxic concentrations (0.3-1
\iM), SDZ PSC 833 and SDZ 280-446
produced an almost complete rever-
sal of the high taxol resistance of the
multidrug-resistant tumor cells,
whereas only partial restoration of
sensitivity to taxol was achieved with
verapamil. Conclusion: SDZ PSC 833
and SDZ 280-446 can restore the
normal taxol sensitivity of highly
resistant multidrug-resistant tumor
cells. Implications: The combination
of taxol with SDZ PSC 833 or SDZ
280-446 may be recommended for
treatment of multidrug-resistant can-
cers. [J Natl Cancer Inst 85:478-483,
1993]
Taxol (NSC-125973) is a new anti-
cancer agent (7,2) presently undergoing
phase I and II clinical trials (3,4). This
drug is isolated from trees of the genus
Taxus, and its ability to arrest cell
proliferation in the G2 and M phases of
the cell cycle is well documented (5,6).
This capacity correlates with its un-
usual properties of interaction with
tubulin in vitro (hyperstabilization of
microtubules) (7).
Unfortunately, a major mechanism of
cellular resistance to taxol is the
increased drug efflux out of cells that
display the "classic" multidrug-
resistant phenotype. An increased ca-
pacity to pump out a variety of drugs
with unrelated structures and intracellu-
lar targets (e.g., vinca alkaloids, doxo-
rubicin, etoposide, dactinomycin, and
colchicine) correlates with increased
levels of mdr gene-encoded membrane
glycoproteins (P-glycoprotein) (7,8).
A variety of agents can decrease in
vitro the drug resistance of multidrug-
resistant tumor cells and sometimes
completely restore their sensitivity to
chemotherapeutic agents. Such chemo-
sensitizers belong to various structural
classes. By interfering with the efflux
function of P-glycoprotein (Pgp), they
can decrease drug resistance or can
restore drug sensitivity by restoring the
normal drug accumulation and distribu-
tion within the multidrug-resistant tu-
mor cell (7,5). Among these chemo-
sensitizers, the calcium channel blocker
verapamil (7) has been the most com-
monly studied. Nevertheless, very po-
tent chemosensitizers have been most
commonly identified among cyclo-
sporines (9,70) and cyclopeptolides
(77) derived from a Fungi imperfecti
(Septoria sp.). Extensive studies of
chemically modified derivatives of
cyclosporines and cyclopeptolides led
to the selection of the two strongest,
nearly equipotent chemosensitizers
identified to date: the cyclosporine
derivative SDZ PSC 833 and the
semisynthetic cyclopeptolide SDZ
280-446 (77,72).
How taxol is processed by Pgp is
unknown, and whether SDZ PSC 833
and SDZ 280-446 could restore a
normal sensitivity to taxol was not
predictable. The present study was,
thus, aimed at (a) measuring the level
of taxol resistance displayed by two
multidrug-resistant tumor cell lines ex-
tensively studied in our laboratory and
(b) testing whether taxol resistance
could be modulated by verapamil, SDZ
PSC 833, and SDZ 280-446.
Materials and Methods
Cell Lines
Parental and multidrug-resistant Chinese ham-
ster ovary (CHO) cells (13) were obtained from
Dr. V. Ling (Ontario Cancer Institute, Toronto,
Canada). Parental and multidrug-resistant murine
monocytic leukemia P388 cells (14) were ob-
tained from Dr. M. Grandi (Farmitalia Carlo
Erba Research Center. Milan, Italy). The
multidrug-resistant P388 cell line has been
selected by growth in the presence of doxo-
rubicin for the multidrug-resistant phenotype
(14). The multidrug-resistant CHO cell line has
been selected by growth in the presence of
colchicine for the multidrug-resistant pbenotype
(13). Detailed information on the properties of
these cell lines (i.e., sensitivity to various drugs
and effects of various chemosensitizers) has been
published by our laboratory (9-12).
*See "Notes" section following "References."
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The parental CHO cell line (AuxB, subclone
ABISII) and the multidrug-resistant CHO line
(CHRC5 subclone C5S3.2) (13) have been
extensively studied with regard to the capacity of
various cyclosporines (9) and other chemosen-
sitizers (10) to reverse the multidrug-resistant
phenotype in vitro. These studies led to the
development of the novel cyclosporine derivative
SDZ PSC 833 and the novel semisynthetic cyclo-
peptolide SDZ 280-446 (11,12).
The parental P388 line (P388N) and the
multidrug-resistant P388 line (P388-DoxR) (14)
have been used to compare in vitro the
resistance-modulating activity of FK-506 and
cyclosporin A (15), to evaluate the restoration of
daunomycin retention in vitro by a variety of
chemosensitizers (16), and to select the SDZ
PSC 833 (12,17) and SDZ 280-446 (//) develop-
ment compounds.
Anticancer Drugs and
Chemosensitizers
For preliminary experiments aimed at testing
the taxol resistance of our cell lines, we obtained
taxol (from Taxus baccala) from the National
Cancer Institute, National Institutes of Health,
Bethesda, Md. For subsequent experiments aimed
at reversing the taxol resistance of our multidrug-
resistant cell lines, we purchased taxol (from
Taxus brevifolia) from Calbiochem AG, Buchs,
Switzerland. The laxol was prepared as a 10-mg/
mL stock solution in pure ethanol. Verapamil
was purchased from Sigma Chemical Co. (St.
Louis, Mo.) and prepared as a 100-mAf stock
solution in pure ethanol. SDZ PSC 833 and SDZ
280-446 were synthesized by Sandoz Pharma
Ltd. (Basel, Switzerland) and were prepared as
10-mAf stock solutions in ethanol.
Chemosensitizer Capacity Assay
Cell cultures were prepared as described
previously (9). Briefly, the cultures were made to
a final volume of 0.2 mL in 96-well microplates
at 37 °C in a humidified atmosphere of 7% CO2
and 93% air. Three-day cultures of P388 cells
were initiated with 2000 parental P388 cells or
5000 multidrug-resistant P388 cells per well.
Five-day cultures of CHO cells were initiated
with 400 parental CHO cells or 800 multidrug-
resistant CHO cells per well. Growth was
measured by a colorimetric assay, as described
previously (9).
The cell growth inhibitory effect of the
chemosensitizer alone, in the presence of the
taxol solvent (ethanol), was expressed as percent
of the growth level obtained in the absence of
both chemosensitizer and taxol, but in the
presence of their solvent (ethanol) (10,12).
The taxol \CK (the concentration producing
50% inhibition of cell growth) was calculated
from the dose-response curves obtained by
plotting the measured growth versus the taxol
concentration, as shown in Fig. 1. A whole range
of IC^ values were obtained in the presence of
the chemosensitizer (verapamil, SDZ PSC 833,
or SDZ 280-446A) (i.e., ICjo+); values were also
obtained in the absence of chemosensitizer, but
in the presence of its solvent (10,12) (i.e., IC,,,-).
The increases of taxol sensitivity, or "gains" in
sensitivity, were given by the ratio IC^/ICy,*,
and a gain was calculated for each chemosen-
sitizer concentration ( / / ) .
Results
Taxol Resistance
The multidrug-resistant P388 cells
were approximately 283-fold more re-
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Fig. 1. Taxol-mediated cell growth inhibition. Results from a typical experiment showing cell growth (as percent of control growth; Y-axes) as a function
of the taxol concentration (as nM; X-axes). Cell growth was measured by the optical density and taken as 100% in control culture wells (cells exposed to
solvent only, run on each microculture plate). Dose-response curves obtained with P388 and CHO cell lines are shown, respectively, at the top and bottom
of the figure (open symbols and solid lines for multidrug-resistant cells, and closed symbols and broken lines for parental cells). On each graph, curves
from right to left were obtained in the presence of increasing concentrations of SDZ PSC 833 or SDZ 280-446 (0, 0.01, 0.03, 0.1, 0.3, and 1 \tM) or of
verapamil (0, 1, 3. 10, and 30 \LM).
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sistant to taxol than the parental P388
cells (Table 1>. This increase compares
with mean values of 130-fold for
colchicine, 158-fold for daunomycin,
101-fold for doxorubicin, 140-fold for
etoposide, and 158-fold for vincristine
(12).
The multidrug-resistant CHO cells
were approximately 36-fold more re-
sistant to taxol than the parental CHO
cells (Table 1). This increase compares
with mean values of 54-fold for col-
chicine, 93-fold for daunomycin, 47-
fold for etoposide, and 28-fold for
vincristine (72). Higher relative resist-
ance indices (Table 1) were observed
for the P388 cells than for the CHO
cells. This result may be partly due to
the fact that the parental P388 cells
were not sensitizable by Pgp-directed
chemosensitizers (15,16) and did not
express immunodetectable levels of
Pgp (16), whereas the parental CHO
cells themselves displayed a low level
of innate resistance (9,10); this low-
level resistance is presumably associ-
ated with their expression of low levels
of Pgp (18,19).
remained in the 4-6 nM range for
concentrations of SDZ PSC 833 and
SDZ 280-446 of 0.01 to 1.0
 iiM. There
was also no decrease in the taxol I C ^
of the parental P388 cells for verapamil
concentrations up to 30 \iM. Similarly,
no major growth inhibition of the
parental P388 cells was caused by the
chemosensitizers alone at concentra-
tions below 1 JJLM (Fig. 2). Thus, our
strongest chemosensitizers (SDZ PSC
833 and SDZ 280-446), did not signifi-
cantly sensitize (less than twofold
increase) the parental P388 cells to
taxol, as has been found with other
drugs (colchicine, vincristine, dauno-
mycin, doxorubicin, and etoposide) and
with Pgp probes (rhodamine 123 and
others) (11,12,16).
In the case of the multidrug-resistant
P388 cells, a virtually complete rever-
sal of taxol resistance could be
achieved with SDZ PSC 833 and SDZ
280-446 but not verapamil. Indeed, a
taxol ICso of about 1800 nM, as
obtained in the absence of any chemo-
sensitizer, could be reduced to about 6
nM in the presence of 1 \iM of SDZ
PSC 833 or SDZ 280-446 (Table 2).
These chemosensitizer concentrations
were not inhibitory (<20% inhibition)
by themselves for multidrug-resistant
P388 cell growth (Fig. 2). At a
concentration at which it was not
substantially inhibitory by itself (1
\iM), verapamil could sensitize the
cells only weakly (taxol I C ^ of about
700 nM); at a concentration (30 \iM) at
which it slightly inhibited multidrug-
resistant P388 cell growth by itself
(Fig. 2), verapamil still could not bring
the taxol IC50 to its expected baseline
of 4-6 nM (Table 2). (The expected
baseline was the range of IC50 values
obtained with this type of assay with a
panel of sensitive cell lines.)
Chemosensitization of CHO Cells
The taxol I C ^ of about 50 nM
shown by the parental^gHO cells in the
absence of chemosensitizer could be
reduced to the apparent baseline of 2-4
nM by the three chemosensitizers
(Table 2). SDZ PSC 833 and SDZ
280-446 were stronger chemosensitizers
Chemosensitization of P388 CeUs
No sensitization of the parental P388
cells could be obtained by the chemo-
sensitizers tested (verapamil, SDZ PSC
833, and SDZ 280-446). The taxol I C ^
Table 1. Anticancer drug resistance of P388 and
CHO cell lines
Cell line*
Anticancer drug
Colchicinef
Daunomycint
Doxorubicint
Etoposidef
Vincristinet
Taxol
Parent cell
Multidrug-
resistant
cell IC,ot
P388
130
158
101
140
158
283
6.1 ± 0.7
1729 ± 272
CHO
54
93
ND
47
28
36
50.8 ± 13.6
1828 ± 26
•Unless otherwise specified, numbers = rela-
tive resistance index (multidrug-resistant cell
ICjo/parent cell ICJO). ND = not determined.
t Indices calculated using ICjo values pre-
viously obtained and published by our group
(12).
tMean values ± SD of 20 determinations
within four individual experiments.
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Fig. 2. Chemosensitizer-induced
cell growth inhibition. Cell growth
inhibition (as percent of control
growth; Y-axes) is shown as a
function of chemosensitizer con-
centration (as \iM\ X-axes).
Growth inhibition was calculated
as the difference between growth
in the absence and presence of
chemosensitizer. Open symbols
represent parental cells, and closed
symbols represent multidrug-
resistant cells (circles for SDZ
PSC 833, squares for SDZ
280-446, and triangles for ve-
rapamil). Values are means of two
to four experiments.
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Table 2. Taxol resistance-modulating activity of SDZ PSC 833, SDZ 280-446, and verapamil for P388 and CHO ceU lines
Chemosensitizer
SDZ PSC 833
SDZ 280-446
Verapamil
Concentration,* \tM
0
0.01
0.03
0.1
0.3
1
0
0.01
0.03
0.1
0.3
1
0
1
3
10
30
Parent
6.3 ± 0.9
5.5 ± 0.2
4.9 ± 0.2
5.2 ± 1.1
4.5 ± 0.9
4.5 ± 1.8
6.0 ± 0.8
5.1 ± 0.2
4.7 ± 0.6
4.5 ± 0.4
4.7 ±
5.2 ±
5.9 ± (
4.7 ±
3.9 ±
4.2 ±
3.7 ±
.1
.2
).7
.2
.5
.3
.6
Taxol
P388 cells
Multidrug-resistant
1812 ± 151
665 ± 218
241 ± 179
38.5 ± 24
10.9 ± 7.1
6.3 ± 1.6
1760 ± 195
975 ± 141
518 ± 116
6 9 + 3 3
22.3 ± 8.9
7.2 ± 1.0
1613 ± 428
742 ± 311
246 ± 91
60.7 ± 16
18.5 ± 3.3
IC,n, aM
Parent
50.2 i
5.5 i
3.9 :
4.0 i
3.7 i
3.4 i
49.7 i
8.3 :
5.7 :
4.4 :
3.9 :
3.5 :
52.4 :
31.7 :
22.3 :
4.2 :
t 13.0
t0.4
t 1.7
t 1.5
t 1.3
t 1.3
t 14.6
t0.5
t 0.9
t 1.8
t 1.6
t 1.3
t 17
t 20
t 25
t 1.6
2.7 ± 0.8
CHO cells
Multidiug-resistant
1662 1
994 i
195 i
18.3 i
7.3 ±
3.0 ±
1886 i
835 d
221 i
253 d
10.8 i
3.8 i
1950 1
1226 i
352 i
66 i
15 i
: 344
t 170
t 52
: 2.7
t 0.9
: 0 . 5
i 223
t 4 8
t 115
t 5.2
t 3.8
t 0.9
t 87
t 325
t 60
t 7.6
t 5.6
*The same solvent concentration was present in all samples. Mean value of two to four experiments ± SD.
than verapamil, inasmuch as this base-
line was approached by 0.03 \LM SDZ
PSC 833 and 0.1 \yJ4 SDZ 280-446 but
required 10 \iM verapamil. The paren-
tal CHO cells were slightly resistant to
the multidrug resistance-modifying
agents, with higher drug I C ^ than for
parental tumor cell lines of other
origins (e.g., L1210 and KB-3.1), as
observed earlier with several other
drugs (e.g., colchicine and etoposide)
and with these and other chemosen-
sitizers (e.g., amiodarone and
quinidine) (9-72). The resistance of the
parental CHO cells can be abrogated by
very low concentrations of strong
chemosensitizers or by higher doses of
weak chemosensitizers (unpublished
data from the study of nearly 1000
compounds). This chemosensitizing ac-
tivity can probably be explained by the
inhibition of the small amounts of Pgp
expressed by the parental CHO cells
(18,19). With little Pgp function to
neutralize, the maximum gains in sen-
sitivity were, of course, correspon-
dingly low (<20-fold) (9-12).
The multidrug-resistant CHO cells
were highly resistant to taxol, with an
ICJO of about 1800 nAf, but were
completely sensitizable by 1 u-W SDZ
PSC 833 or SDZ 280-446 (Table 2).
Those chemosensitizer concentrations
gave no detectable inhibition of
multidrug-resistant CHO cell growth
(Fig. 2). Moreover, even 30 \iM
verapamil could not bring the taxol
ICJO to the apparent 2-4 nA/ baseline,
although it produced a taxol I C ^ of
about 2.7 nA/ in untreated parental
CHO cells.
Discussion
Taxol is a promising anticancer drug
(20,21), as shown by recent clinical
studies (2-4), but it belongs to the class
of compounds that can be effluxed by
multidrug-resistant cells expressing Pgp
(7). Fortunately, as shown in Table 2
and Fig. 2, taxol resistance can be
virtually neutralized by nontoxic con-
centrations (0.3-1 \iM) of SDZ PSC
833 or SDZ 280-446.
In the present study, gains in taxol
sensitivity of 250- to 300-fold could be
reached with the multidrug-resistant
P388 cells. (For calculation of gains,
see the "Materials and Methods"
section.) In equimolar comparisons,
SDZ PSC 833 seemed to be slightly
more active than SDZ 280-446 for the
reversal of taxol resistance, but the
difference was small (about twofold).
Much higher concentrations of ver-
apamil were required to obtain compar-
able gains.
With the multidrug-resistant CHO
cells, gains of about ninefold and about
550-fold could be obtained by 0.03 \yM
and 1 \LM, respectively, of either SDZ
PSC 833 or SDZ 280-446. These
chemosensitizers appeared to be
equipotent for chemosensitizing this
cell line and much stronger than
verapamil: A maximum gain of sensi-
tization of 130-fold required 30 \LM
verapamil.
The two multidrug-resistant tumor
cell lines in the present study displayed
a level of taxol resistance similar to
their levels of resistance shown for
several other drugs of unrelated struc-
ture and mode of action (Table 1). In
contrast, a taxol-resistant J774.2 cell
subline, obtained by growing the cells
with taxol (22), displayed a much
higher resistance to taxol (833-fold),
and showed clearly weaker cross-
resistance to colchicine (58-fold), vin-
blastine (43-fold), puromycin (97-fold),
doxorubicin (128-fold), and dactinomy-
cin (88-fold). These cells exhibited a
decreased accumulation of taxol in
comparison with sensitive cells, which
could be correlated with the presence
of a 135-kd phosphoprotein (22).
The multidrug-resistant phenotype of
tumor cells, even when mediated only
by Pgp overexpression (i.e., with no
other known resistance mechanism),
does not display constant features:
Each Pgp-expressing multidrug-
resistant cell line can display its own
pattern of cross-resistance (7,8). There-
fore, it could be expected that a given
multidrug-resistant cell line may also
show different degrees of chemosensi-
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tization by different chemosensitizers
for different drugs.
Distinct drug binding-transport sites
on the Pgp might indeed exist for
different drugs or groups of drugs.
Colchicine does not inhibit the in vitro
photolabeling of Pgp by a vinblastine
analog, whereas vinca alkaloids, ver-
apamil, and diltiazem were able to do
so (23,24). Both calcium channel
blockers, verapamil and diltiazem, were
also able to inhibit Pgp photolabeling
by a cyclosporine analog, whereas
colchicine in similar concentrations had
no effect (25). Thus, the colchicine
binding-transport site on Pgp might be
distinct from the vinca alkaloid site.
In a recent study, the two most
commonly used chemosensitizers, ver-
apamil and quinidine, could not restore
the retention of rhodamine 123 in the
same multidrug-resistant P388 cell line
as that used in the present study (26),
although they could restore daunomycin
retention (76); in contrast, amiodarone,
cyclosporin A, SDZ 280-446, and SDZ
PSC 833 could restore the retention of
both Pgp-function probes (16,26).
These results show that different che-
mosensitizers may differently affect
drug transport by Pgp molecules.
Besides this variable efficacy of
chemosensitizers mediated by the wild-
type Pgp of multidrug-resistant cells, an
additional variability in the gains of
sensitivity may depend on Pgp polymor-
phism resulting from somatic mutations
in response to selective pressure. Typ-
ically, a series of multidrug-resistant KB
epidermoid carcinoma (ATCC CCL17)
cell lines, which had been obtained by
independent selection with colchicine,
vinblastine, or doxorubicin, displayed a
definitely preferential relative resistance
to the drug used for selection, although
they displayed a broad cross-resistance
to the other drugs (8). Single point
mutations sufficient to dramatically af-
fect the profile of resistance conferred
by the wild-type Pgp, such as a marked
alteration of the relative resistance to
colchicine, vinblastine, and doxorubicin,
were caused by a single glycine-valine
interchange (27). Similarly, mutations in
the hamster pgpl gene conferred a dis-
tinctive multidrug-resistant profile to
dactinomycin-selected sublines of multi-
drug-resistant DC/3F cells: Highest re-
sistance was now for dactinomycin in-
stead of colchicine as in the parental
line (28). Thus, while one mutation
increased colchicine resistance in one
instance (27), a different mutation de-
creased it in the other (28). Finally,
multidrug-resistant J774.2 sublines se-
lected by growth in the presence of
colchicine, vinblastine, or taxol devel-
oped heterogeneous forms of multidrug
resistance-associated glycoproteins
(29-31). Such glycoproteins of the taxol-
resistant sublines were found to be
similar but not identical to the classic
Pgp expressed in vinblastine- and
colchicine-resistant sublines derived
from the same parent (29,30).
Eventually, the taxol-specific molecu-
lar variants (24,25) of the multidrug
resistance-associated glycoproteins
might display altered chemosensitization
profiles in comparison with the bona
fide mdrl -encoded Pgp, although the
taxol resistance of resistant CHO cells
could be reversed by verapamil (32). In
this respect, it would thus be interesting
to study how active SDZ PSC 833 and
SDZ 280-446 are with such taxol-
induced variants of multidrug resistance-
associated glycoproteins.
In conclusion, precisely how taxol is
processed by Pgp molecules remains
unknown. Nonetheless, tumor cell resist-
ance to taxol can be abrogated by either
the cyclosporine SDZ PSC 833 or the
cyclopeptolide SDZ 280-446. The com-
bination of taxol with either SDZ PSC
833 or SDZ 280-446 may be recom-
mended for the treatment of multidrug-
resistant cancers.
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Growth Inhibition of Human
Lymphoma Cell Lines by the
Marine Products, Dolastatins
10 and 15
Margaret Beckwith, Walter J.
Urba, Dan L. Longo*
Background: Dolastatins 10 and 15
are small peptides isolated from the
marine sea hare Dolabella auricu-
laria. In vitro studies of these pep-
tides have demonstrated antlmitotic
and antlproliferative activity and
growth inhibition in hematopoietic
progenitor cells. Purpose: The pur-
pose of our in vitro study was to
determine the biological effects of
these marine peptides on growth of
human lymphoma cell lines and to
investigate mechanisms by which the
dolastatins may act Methods: Cell
lines DB, HT, RL, and SR were
grown from the ascites or pleura!
effusion of four patients with lym-
phoma. The DB, HT, and RL cell
lines are of B-cell origin, and the SR
cell line appears to be a less differen-
tiated lymphoid cell type. Cells from
these lines were cultured in the
presence of vincristine or dolastatin
10 or 15. [3H]Thymidine-uptake as-
says were used to measure effects on
DNA synthesis. Cell cycle analysis
using propidlum iodide was per-
formed to measure drug-induced cell-
cycle arrest DNA fragmentation was
used as an assay for drug-induced
apoptosis and was measured by
agarose gel electrophoresis. Results:
In the three B cell lines, dolastatin 10
was more effective than dolastatin
15. Values for concentrations re-
quired for inhibition of proliferation
by 50% (ICso) were .00013-.0013 nM
for dolastatin 10 in each cell line;
values for dolastatin 15 were approx-
imately .13 nM in DB and HT cells
and .0013-.013 nM in RL cells. SR
cells were more sensitive to dola-
statin 15 than to dolastatin 10 (\CM
= .00013-.0013 nM versus .0013-.013
nM). Both dolastatins arrested more
than 70% of cells in mitosis in all cell
lines. This effect was reversed if the
drug was removed by 4 hours, but by
8 hours of exposure, reversal was not
possible. Both dolastatins 10 and 15
produced apoptosis in DB and HT
cells but not in the other two cell
lines. Conclusions: We have demon-
strated that dolastatins 10 and 15
have a profound antiproUferative
effect on four different human
lymphoma cell lines and that the
dolastatins are approximately 3-4
logarithms more effective as anti-
proUferative compounds, on a molar
basis, than vincristine—a clinically
useful, antiproUferative agent These
data support the hypothesis that
apoptosis, as measured by DNA
fragmentation, appears to be a cell-
specific response and may not be
directly related to the antimitotic
effect of the dolostatins. Implications:
Our results suggest that these com-
pounds may be good candidates for
development as antineoplastic agents.
[J Natl Cancer Inst 85:483-^*88,
1993]
In the past few years, there has been
an intensive search for new anti-
neoplastic agents derived from natural
plant or animal sources. These efforts
have revealed many potentially useful
new compounds isolated from marine
animals, including the bryostatins (1-3),
halichondrin B and homohalichondrin
B (4), and the dolastatins (5-8). Among
these natural compounds, the dola-
statins appear to have the greatest
therapeutic potential. The dolastatins
are small peptides or depsipeptides
isolated from the East Indian Ocean sea
hare, Dolabella auricularia; at least 15
unique molecules have been identified
(5-8).
In this report, we have analyzed the
biological effect of two of these
unusual peptides, dolastatins 10 and 15
(5,6), on a panel of human lymphoma
cell lines. Dolastatin 10 consists of four
amino acid residues (dolavaline, valine,
dolaisoleuine, and dolaproine) and has
*See "Notes" section following "References."
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